192869-80-0

Basic information

• Product Name: 7-BENZYL-5,6,7,8-TETRAHYDRO4-CHLORO-PYRIDO[3,4-D]PYRIMIDINE HYDROCHLORIDE
• Synonyms: 7-BENZYL-5,6,7,8-TETRAHYDRO4-CHLORO-PYRIDO[3,4-D]PYRIMIDINE HYDROCHLORIDE;7-BENZYL-4-CHLORO-5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIDINE;7-benzyl-4-chloro-5;7-Benzyl-4-chloro-5,6,7,8-tetrahydro-quinazoline;Pyrido[3,4-d]pyriMidine,4-chloro-5,6,7,8-tetrahydro-7-(phenylMethyl)-;7-Benzyl-5,6,7,8-tetrahydro4-chloro-pyrido[3,4-D]pyriMidine;7-Benzyl-4-chloro-5,6,7,8-tetrahydro-1,3,7-triazanaphthalene;7-BENZYL-4-CHLORO-5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIMIDINE HCL
• CAS NO: 192869-80-0
• Molecular Formula: C₁₄H₁₄ClN₃
• Molecular Weight: 296.2
• Product Categories: CHIRAL CHEMICALS;Heterocycle-Pyrimidine series
• Mol File: 192869-80-0.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 396.568 °C at 760 mmHg
• Flash Point: 193.638 °C
• Appearance: /
• Density: 1.273 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.22±0.20(Predicted)
• CAS DataBase Reference: 7-BENZYL-5,6,7,8-TETRAHYDRO4-CHLORO-PYRIDO[3,4-D]PYRIMIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BENZYL-5,6,7,8-TETRAHYDRO4-CHLORO-PYRIDO[3,4-D]PYRIMIDINE HYDROCHLORIDE(192869-80-0)
• EPA Substance Registry System: 7-BENZYL-5,6,7,8-TETRAHYDRO4-CHLORO-PYRIDO[3,4-D]PYRIMIDINE HYDROCHLORIDE(192869-80-0)

Safety Data

• Hazardous Substances Data: 192869-80-0(Hazardous Substances Data)

Usage

General Description

7-Benzyl-5,6,7,8-tetrahydro-4-chloro-pyrido[3,4-d]pyrimidine hydrochloride is a chemical compound with potential pharmacological properties. It is a tetrahydro-pyrido[3,4-d]pyrimidine derivative, and its hydrochloride form suggests its potential use as a pharmaceutical agent. 7-BENZYL-5,6,7,8-TETRAHYDRO4-CHLORO-PYRIDO[3,4-D]PYRIMIDINE HYDROCHLORIDE may have activity as a central nervous system depressant or may have therapeutic effects on various neurological or psychiatric conditions. The specific properties and potential uses of this chemical compound would require further research and testing to fully elucidate its pharmacological potential.

InChI:InChI=1/C14H14ClN3/c15-14-12-6-7-18(9-13(12)16-10-17-14)8-11-4-2-1-3-5-11/h1-5,10H,6-9H2

Upstream product

• 1053656-41-9 7-benzyl-4-carbonyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 
• 39514-19-7 ethyl 1-benzyl-3-oxo-4-piperidinecarboxylate 
• 6436-90-4 ethyl 2-(benzylamino)acetate 
• 100-46-9 benzylamine 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 
• 69981-00-6 7-benzyl-5,6,7,8-tetrahydro-3H-pyrido[3,4-d]pyrimidin-4-one 
• 6313-33-3 formamidine hydrochloride 
• 62458-96-2 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one 
• 62458-96-2 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-ol 

Downstream Products

• 911010-79-2 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrinidine-4-carbonitrile 
• 911010-81-6 7-benzyl-4-carboxy-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 
• 859825-28-8 7-benzyl-5,6,7,8-tetrahydro-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyrido[3,4-d]pyrimidin-4-amine 

Relevant articles and documents

Process development and scale-up of a selective α1- adrenoceptor antagonist

A synthetic route to a potent and selective α-1-adrenergic receptor antagonist has been developed and demonstrated in a pilot plant. The route has been used in two pilot plant campaigns and has produced RO3203546 in 2.3 and 12.0 kg batch sizes. The first pilot plant campaign focused primarily on the end-game of the process with particular emphasis on the development of a method to isolate the active pharmaceutical ingredient (API). The second pilot plant campaign allowed front-end process improvements to be demonstrated. The reiterative process improvements resulted in an economical process with improved throughput and product quality when compared to the original discovery synthesis.

Inhibitors of HIV-1 attachment: The discovery and structure-activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore

6,6-Fused ring systems including tetrahydroisoquinolines and tetrahydropyrido[3,4-d]pyrimidines have been explored as possible replacements for the piperazine benzamide portion of the HIV-1 attachment inhibitor BMS-663068. In initial studies, the tetrahydroisoquinoline compounds demonstrate sub-nanomolar activity in a HIV-1 pseudotype viral infection assay used as the initial screen for inhibitory activity. Analysis of SARs and approaches to optimization for an improved drug-like profile are examined herein.

HETEROBICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS

A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p3